Pharmaceuticals

ZMC released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 2.191 B, actual EPS CNY 0.3 (forecast EPS CNY 0.39)

ZMC to Release FY2026 Q1 Earnings on April 24 After-Market (BJT), Forecast EPS CNY 0.39

ZMC released FY2025 Annual Earnings on April 10 After-Market (BJT), actual revenue CNY 8.881 B (forecast CNY 8.753 B), actual EPS CNY 0.9099 (forecast CNY 1.195)

ZMC released FY2025 Q4 earnings on April 10 After-Market BJT, actual revenue CNY 2.185 B, actual EPS CNY -0.0685 (forecast EPS CNY 0.37)

ZMC released FY2025 Q3 earnings on October 27 During-Market (BJT), actual revenue CNY 2.372 B, actual EPS CNY 0.2694 (forecast EPS CNY 0.44)

ZMC released FY2025 9 Months Earnings on October 27 During-Market (BJT), actual revenue CNY 6.695 B, actual EPS CNY 0.971

ZMC to Release FY2025 Q3 Earnings on October 28 During-Market (BJT), Forecast EPS CNY 0.44

ZMC released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), Actual Revenue CNY 4.323 B, Actual EPS CNY 0.7

ZMC released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 2.067 B, actual EPS CNY 0.2717 (forecast EPS CNY 0.34)

ZMC to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Zhejiang Medicine Secretary Introduces Some Yiwell Brand Products Suitable for Children

Xinchang Pharmaceutical Successfully Passes US FDA CGMP Inspection

Investor Questions Why Share Price Continues to Fall After Buyback

Zhejiang Medicine Responds to Shareholder Reduction and Buyback Progress

Zhejiang Medicine's Net Profit Soars 273.08% in Q1 2025

ZMC released FY2024 earnings on April 23 After-Market (BJT), actual revenue CNY 9.375 B (forecast CNY 9.603 B), actual EPS CNY 1.2068 (forecast CNY 1.52)

ZMC released FY2024 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 2.262 B, actual EPS CNY 0.3307 (forecast EPS CNY 0.35)

ZMC released FY2025 Q1 earnings on April 23 Pre-Market (BJT), actual revenue CNY 2.255 B, actual EPS CNY 0.43 (forecast EPS CNY 0.27)

Zhejiang Medicine Secures 180 Million Yuan Loan for Stock Repurchase

ZMC to Release FY2025 Q1 Earnings on April 24 Pre-Market BJT, Forecasted EPS CNY 0.27

520690

159992

589720

600216

Shanghai Pharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Final Dividend

Tip Ranks

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

SH PHARMA

Guotai CSI Bio-medicine ETF

SSE Health Care

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Shanghai Pharma

GF CSI All Share Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

China Universal 800 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

Shanghai Pharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Final Dividend

600332

00874

BAIYUNSHAN PH announced that its subsidiary Guangzhou Medicine is acquiring 100% equity of Zhejiang Medical Industry from independent third party Haizheng Pharmaceutical through a public listing method. The latter is a pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products, with a cash consideration of 500 million RMB

AASTOCKS

GYBYS

BAIYUNSHAN PH

BAIYUNSHAN PH fully acquires ZMC distribution company for a consideration of 500 million RMB

According to the Zhitong Finance APP, ZMC announced that Guotou High-Tech plans to reduce its holdings by no more than 9.6164 million shares, or no more than 1% of the company's total share capital, through centralized bidding trading within three months after the announcement date, starting from 15 trading days after the disclosure

Zhitong

Zhejiang Medicine: State Investment High-Tech plans to reduce its holdings by no more than 1% of shares

According to the Zhitong Finance APP, ZMC disclosed its semi-annual report for 2025, reporting revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%; net profit attributable to the parent company of 673 million yuan, a year-on-year increase of 113.52%; net profit excluding non-recurring gains and losses of 665 million yuan, a year-on-year increase of 110.10%; basic earnings per share of 0.70 yuan

Zhejiang Medicine released its semi-annual performance, with a net profit attributable to the parent company of 673 million yuan, a year-on-year increase of 113.52%

Zhejiang Medicine announced that on August 11, 2025, the company completed its share repurchase, accumulating a total of 13.7232 million shares through the centralized bidding method via the Shanghai Stock Exchange system, accounting for 1.43% of the company's current total share capital. The highest repurchase price was RMB 16.09 per share, the lowest price was RMB 13.31 per share, and the average repurchase price was RMB 14.57 per share, with a total amount of funds used being RMB 200 million. The repurchased shares will be used for the subsequent implementation of the employee stock ownership plan or equity incentives

Zhejiang Medicine: Completed the repurchase of 1.43% of shares

Zhejiang Medicine's subsidiary, Xinchang Pharmaceutical Factory, underwent a CGMP on-site inspection by the U.S. FDA from March 4 to March 7, 2025, covering four major systems including the quality system for oral solid preparations and active pharmaceutical ingredients. Xinchang Pharmaceutical successfully passed the inspection, meeting the U.S. drug CGMP quality system requirements, and has received the FDA's on-site inspection report confirming the completion of the inspection

Zhejiang Medicine's subsidiary, Xinchang Pharmaceutical Factory, passed the on-site inspection by the U.S. FDA

On April 14, 2025, Zhejiang Medicine's board of directors approved a share repurchase plan, intending to repurchase shares with funds ranging from 100 million to 200 million yuan. As of May 12, 2025, 440,700 shares have been repurchased, accounting for 0.05% of the total share capital, with repurchase prices ranging from 13.31 yuan to 13.43 yuan, totaling 5.8959 million yuan in funds used. The company will continue to implement the repurchase based on market conditions and disclose progress in a timely manner

Zhejiang Medicine: Has repurchased 440,700 shares with a total amount of funds used of 5.8959 million yuan

According to the Qichacha APP, recently, Shanghai Anke Li Biotechnology Co., Ltd. was established, with Qi Feng as the legal representative and a registered capital of 1 million yuan. The business scope includes: wholesale of cosmetics; retail of cosmetics; sales of Class I medical devices; health consulting services; beauty services; medical beauty services, etc. Qichacha's equity penetration shows that the company is wholly owned by Zhejiang Lai Yi Mei Biomedical Co., Ltd., which is jointly held by Zhejiang Medicine and others

CNI BIOMEDICINE

Zhejiang Medicine and others invest in Shanghai to establish a biotechnology company

Zhejiang Medicine released its 2024 annual performance report, with revenue of 9.375 billion yuan, a year-on-year increase of 20.29%; net profit attributable to shareholders of the parent company was 1.161 billion yuan, a year-on-year increase of 170.11%; net profit excluding non-recurring gains and losses was 1.16 billion yuan, a year-on-year increase of 656.77%; basic earnings per share were 1.21 yuan. The company plans to distribute a cash dividend of 0.37 yuan per share (including tax) to all shareholders

Zhejiang Medicine released its 2024 annual performance, with a net profit attributable to the parent company of 1.161 billion yuan, a year-on-year increase of 170.11%

According to the Zhitong Finance APP, ZMC disclosed its first-quarter report for 2025, showing that the company achieved revenue of 2.255 billion yuan during the reporting period, a year-on-year increase of 0.28%; net profit attributable to the parent company was 409 million yuan, a year-on-year increase of 273.08%; and net profit excluding non-recurring gains and losses was 402 million yuan, a year-on-year increase of 279.23%. Basic earnings per share were 0.43 yuan

Zhejiang Medicine released its first-quarter performance, with a net profit attributable to the parent company of 409 million yuan, a year-on-year increase of 273.08%

ZMC(600216.SH)

Shanghai Pharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Final Dividend

BAIYUNSHAN PH fully acquires ZMC distribution company for a consideration of 500 million RMB

Zhejiang Medicine: State Investment High-Tech plans to reduce its holdings by no more than 1% of shares

Zhejiang Medicine released its semi-annual performance, with a net profit attributable to the parent company of 673 million yuan, a year-on-year increase of 113.52%

Zhejiang Medicine: Completed the repurchase of 1.43% of shares

Zhejiang Medicine's subsidiary, Xinchang Pharmaceutical Factory, passed the on-site inspection by the U.S. FDA

Zhejiang Medicine: Has repurchased 440,700 shares with a total amount of funds used of 5.8959 million yuan

Zhejiang Medicine and others invest in Shanghai to establish a biotechnology company

Zhejiang Medicine released its 2024 annual performance, with a net profit attributable to the parent company of 1.161 billion yuan, a year-on-year increase of 170.11%

Zhejiang Medicine released its first-quarter performance, with a net profit attributable to the parent company of 409 million yuan, a year-on-year increase of 273.08%